Somto Nwaedozie, MD
Advanced Heart Failure and Transplant Cardiology · Madison, WINPI 1487216560
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $13,571 of the $16,463 with a category attached, or 82.4%. Philips North America LLC accounts for 80.3% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $14,995 and has fallen 95.2% since, to $713 in 2025.
Across 54 payments — averaging $304.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$13K
- Abbott$1K
- Boston Scientific$627
- Actelion Pharmaceuticals US, Inc.$319
- Amgen$271
- Endotronix, Inc.$223
- plus $482 from 6 others
What the payments were for
- Grants$6274%
- Travel & lodging$13,57182%
- Food & beverage$2,07513%
- Education$1891%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 18 | $13,227 |
| Abbott | 16 | $1,313 |
| Boston Scientific | 2 | $627 |
| Actelion Pharmaceuticals US, Inc. | 3 | $319 |
| Amgen | 5 | $271 |
| Endotronix, Inc. | 2 | $223 |
| Impulse Dynamics (USA) Inc. | 2 | $183 |
| Cardiovascular Systems Inc. | 1 | $156 |
| Abiomed | 2 | $69 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $41 |
| Medtronic | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few advanced heart failure and transplant cardiology providers in Wisconsinto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 33 | $29,419 |
| Ezetimibe | 11 | $428 |
| Metoprolol Succinate | 23 | $391 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 15 | $333 |
| ClopidogrelClopidogrel Bisulfate | 11 | $197 |
| Losartan Potassium | 16 | $129 |
| Atorvastatin Calcium | 25 | $128 |
| Furosemide | 14 | $89 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Madison
- Sofia MasriMadison$6K
- Maryl JohnsonMadison$5K
- David MurrayMadison$1K
- Veli TopkaraMadison$658
- Aurangzeb BaberMadison$443
- Line KemeyouMadison$209
- Dianne ZwickeMilwaukee$56K
- Ravi DhingraMilwaukee$27K
- Nasir SulemanjeeMilwaukee$16K
- Jose Iturrizaga MurrietaSheboygan$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.